Please login to the form below

Not currently logged in
Email:
Password:

Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel

They will join the board of directors

Moncef SlaouiGenome editing group Intellia Therapeutics has appointed Moncef Slaoui and Frank Verwiel to join its board of directors at a time when the board is establishing a Science and Technology Committee, which will be chaired by Slaoui.

Slaoui (pictured right) recently retired as chairman of vaccines at GlaxoSmithKline (GSK), where he also served on the company’s executive team and board of directors for eleven years.

During his 30-year career at GSK, he worked on drug discovery and development, business development, new product development and commercial organisations.

He was also chairman of GSK’s global R&D organisation for eight years and led the global integration of Novartis’ vaccine unit into GSK.

Additionally, Dr Frank Verwiel (pictured left)Frank Verwiel joins the group’s board of directors after serving ObsEva SA, a biopharmaceutical company focussed on women’s reproductive health.

He has held numerous leadership roles including president and CEO of Aptalis Pharma prior to its acquisition by Forest Laboratories.

Verwiel has also served at Merck & Co, where he was vice president and was general manager at Merck Sharpe Dohme’s operations in the Netherlands.

Perry Karsen, chair of the board of directors at Intellia Therapeutics, said: “We are very pleased to welcome Drs Slaoui and Verwiel to our Board of Directors. They bring decades of scientific, operational, business and strategic experience in the pharmaceutical and biotech industries to Intellia.

“We look forward to their guidance as we continue to advance our genome editing technology to patients.”

3rd August 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics